Faced with the Phase III failure of Desmoteplase for stroke in June, Forest Laboratories has bailed on its development partnership with Paion. Paion's other unlucky licensee, a troubled Lundbeck, said two months ago that the late-stage study revealed no statistically significant difference between the way Desmoteplase patients responded when compared to a group taking a placebo. Paion, for its part, says it is evaluating other options while Lundbeck has yet to announce its decision pending a full analysis of the data. Forest's departure does carry some benefits, though, as it pays out â‚¬4.3 million to cover research and development costs.
- read the release for more